Kiniksa Pharmaceuticals, Ltd. (KNSA) DCF Valuation

Kiniksa Pharmaceuticals, Ltd. (KNSA) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

Kiniksa Pharmaceuticals, Ltd. (KNSA) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Designed for accuracy, our KNSA DCF Calculator empowers you to assess Kiniksa Pharmaceuticals, Ltd. valuation using real-world financial data, offering complete flexibility to modify all essential parameters for enhanced projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 38.5 220.2 270.3 353.2 461.6 603.2 788.3 1,030.2
Revenue Growth, % 0 0 0 471.24 22.74 30.69 30.69 30.69 30.69 30.69
EBITDA -167.9 -152.4 -154.3 9.8 -22.9 67.8 88.6 115.8 151.3 197.8
EBITDA, % 100 100 -400.27 4.44 -8.46 19.2 19.2 19.2 19.2 19.2
Depreciation 3.3 3.8 4.1 4.2 2.3 150.7 197.0 257.4 336.4 439.7
Depreciation, % 100 100 10.6 1.92 0.86621 42.68 42.68 42.68 42.68 42.68
EBIT -171.2 -156.2 -158.4 5.6 -25.2 65.8 86.0 112.4 146.9 192.0
EBIT, % 100 100 -410.87 2.52 -9.32 18.64 18.64 18.64 18.64 18.64
Total Cash 233.4 323.5 182.2 190.6 206.4 327.0 427.4 558.5 729.9 953.8
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 4.0 20.3 21.3
Account Receivables, % 100 100 10.34 9.23 7.87
Inventories .0 .0 3.7 21.6 31.1 163.1 213.1 278.5 364.0 475.7
Inventories, % 100 100 9.53 9.81 11.52 46.17 46.17 46.17 46.17 46.17
Accounts Payable 5.7 .5 1.9 7.9 8.2 149.4 195.2 255.1 333.4 435.8
Accounts Payable, % 100 100 4.85 3.59 3.05 42.3 42.3 42.3 42.3 42.3
Capital Expenditure -3.2 -.3 -20.4 -.1 -.1 -37.5 -49.0 -64.0 -83.7 -109.3
Capital Expenditure, % 100 100 -52.97 -0.04768826 -0.04810201 -10.61 -10.61 -10.61 -10.61 -10.61
Tax Rate, % 184.58 184.58 184.58 184.58 184.58 184.58 184.58 184.58 184.58 184.58
EBITAT -169.0 -161.4 -159.8 92.3 21.3 52.5 68.6 89.7 117.2 153.1
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -163.3 -163.0 -182.4 68.2 13.4 35.6 163.1 213.2 278.6 364.1
WACC, % 6.08 6.08 6.08 6.08 6.04 6.07 6.07 6.07 6.07 6.07
PV UFCF
SUM PV UFCF 848.3
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 371
Terminal Value 9,122
Present Terminal Value 6,793
Enterprise Value 7,642
Net Debt -96
Equity Value 7,737
Diluted Shares Outstanding, MM 72
Equity Value Per Share 107.58

What You Will Get

  • Real KNSA Financials: Access to historical and projected data for precise valuation.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
  • Scenario Analysis: Explore various scenarios to assess Kiniksa Pharmaceuticals' future performance.
  • User-Friendly Design: Crafted for industry professionals while remaining approachable for newcomers.

Key Features

  • Comprehensive Financial Data: Gain access to precise pre-loaded historical figures and future forecasts for Kiniksa Pharmaceuticals, Ltd. (KNSA).
  • Tailorable Forecast Inputs: Modify highlighted fields such as WACC, growth projections, and profit margins.
  • Automated Calculations: Enjoy real-time updates to DCF, Net Present Value (NPV), and cash flow assessments.
  • User-Friendly Dashboard: View intuitive charts and summaries for a clear understanding of your valuation insights.
  • Designed for All Levels: An easy-to-navigate format suitable for investors, CFOs, and consultants alike.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Kiniksa Pharmaceuticals data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Kiniksa Pharmaceuticals' intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Kiniksa Pharmaceuticals, Ltd. (KNSA)?

  • Designed for Industry Experts: A sophisticated tool utilized by analysts, CFOs, and pharmaceutical consultants.
  • Accurate Financial Data: Kiniksa’s historical and projected financials are preloaded for precision.
  • Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
  • Comprehensive Outputs: Instantly calculates intrinsic value, NPV, and essential metrics.
  • User-Friendly Interface: Step-by-step guidance to facilitate your calculations.

Who Should Use This Product?

  • Investors: Assess Kiniksa Pharmaceuticals' valuation prior to making investment decisions.
  • CFOs and Financial Analysts: Optimize valuation methodologies and evaluate financial forecasts.
  • Startup Founders: Understand valuation practices of established biotech companies like Kiniksa Pharmaceuticals.
  • Consultants: Provide comprehensive valuation reports for clients in the pharmaceutical sector.
  • Students and Educators: Utilize real-time data to study and teach valuation strategies.

What the Template Contains

  • Pre-Filled Data: Includes Kiniksa Pharmaceuticals’ historical financials and projections.
  • Discounted Cash Flow Model: Editable DCF valuation model with automated calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on user-defined inputs.
  • Key Financial Ratios: Evaluate Kiniksa's profitability, efficiency, and financial leverage.
  • Customizable Inputs: Easily modify revenue growth rates, margins, and tax assumptions.
  • Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.

No products were found matching.